Skip to main content
Premium Trial:

Request an Annual Quote

Barry Polisky, Bruce Thaw, James Rothman, Steven Quay

Premium
MDRNA has appointed Barry Polisky as its CSO.
 
Polisky will replace Steven Quay, who will be stepping down from his roles as CSO and chairman of the company’s board of directors and scientific advisory board.
 
Previously, Polisky served as research vice president of Merck. He also served as CSO of Sirna Therapeutics prior to its acquisition by Merck. He holds a PhD in molecular biology from the University of Colorado.
 
MDRNA also announced that Bruce Thaw, lead independent director of the company, will assume the role of chairman of the board. James Rothman, a member of MDRNA’s scientific advisory board, has also been named chairman of the SAB.
 
In conjunction with the appointments, MDRNA said that former President, CEO, and Chairman Steven Quay will step down from the company. He will remain a member of both boards.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.